Altheos, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://altheos.net
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Altheos, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01668524
- Locations
- 🇺🇸
Sall Research Medical Center, Artesia, California, United States
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
Phase 1
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: Stage 1 - ATS907 - Dose 2Drug: Stage 1 - ATS907 - Dose 1Drug: Stage 1 - ATS907 - Dose 4Drug: Stage 1 - VehicleDrug: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1Drug: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1Drug: Stage 1 - ATS907 - Dose 3
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Altheos, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT01520116
News
No news found